Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Gemphire Therapeutics Inc. (NASDAQ: GEMP).

Full DD Report for GEMP

You must become a subscriber to view this report.


Recent News from (NASDAQ: GEMP)

Midday Gainers / Losers (05/16/2018)
Gainers: IHT +50% . BLNK +36% . EBIO +21% . GEMP +18% . VNET +18% . FSI +16% . ABAX +16% . BBOX +13% . ASNA +14% . NSPR +14% . More news on: Innsuites Hospitality Trust, Blink Charging Co., Eleven Biotherapeutics, Inc., Stocks on the move, , Read more ....
Source: SeekingAlpha
Date: May, 16 2018 13:00
Premarket Gainers as of 9:05 am (5/16/2018)
GEMP +19% . More news on: Gemphire Therapeutics, Boot Barn Holdings, Blink Charging Co., Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: May, 16 2018 09:25
Gemphire Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update
LIVONIA, Mich., May 08, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohe...
Source: GlobeNewswire
Date: May, 08 2018 16:01
Gemphire Therapeutics Announces the Appointment of Steven Gullans, Ph.D., as President and Chief Executive Officer
LIVONIA, Mich., May 03, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia and Nonalcoholic Steatohepatitis (NASH), today...
Source: GlobeNewswire
Date: May, 03 2018 16:01
Cirius Therapeutics completes enrollment in mid-stage study of lead candidate in NASH
Privately held Cirius Therapeutics announces that it has reached the enrollment target in a Phase 2b clinical trial, EMMINENCE , assessing lead candidate MSDC-0602K in patients with NASH and liver fibrosis. More news on: Conatus Pharmaceuticals, Galectin Therapeutics, Inc., Navidea Bi...
Source: SeekingAlpha
Date: May, 02 2018 10:47
Gemphire Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(C)(4)
LIVONIA, Mich., April 12, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia and Nonalcoholic Steatohepatitis (NASH), tod...
Source: GlobeNewswire
Date: April, 12 2018 16:01
Key events next week - healthcare
Noteworthy events for the week of March 18 - 24 for healthcare investors: More news on: Spark Therapeutics, SELLAS Life Sciences Group, Inc., Atara Biotherapeutics, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: March, 16 2018 10:25
After Hours Gainers / Losers (3/15/2018)
Top gainers: AMRS +19.7% . KODK +10.1% . KEYW +9.7% . CATB +5.7% . AUPH +3.5% . More news on: Amyris, Inc., Eastman Kodak Co., KEYW Holding, Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: March, 15 2018 17:37
Gemphire Therapeutics beats by $0.03
Gemphire Therapeutics (NASDAQ: GEMP ): Q4 EPS of -$0.63 beats by $0.03 . More news on: Gemphire Therapeutics, Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: March, 15 2018 17:36
Gemphire expects data readout from mid-stage study of gemcabene next quarter
Gemphire Therapeutics (NASDAQ: GEMP ) announces its 2018 clinical milestones : More news on: Gemphire Therapeutics, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: March, 15 2018 16:54

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-176.416.376.505.95304,263
2017-09-0710.0210.0310.489.0848,759
2017-09-0610.6410.0410.649.8856,775
2017-09-059.6010.4710.509.2078,205
2017-09-019.709.679.939.5252,184

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-05-249,17618,93648.4580Short
2018-05-2320,34646,75643.5153Short
2018-05-2218,98535,85152.9553Short
2018-05-2125,45271,42135.6366Short
2018-05-1812,72423,82253.4128Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on GEMP.


About Gemphire Therapeutics Inc. (NASDAQ: GEMP)

Logo for Gemphire Therapeutics Inc. (NASDAQ: GEMP)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $72,409,831 - 05/11/2018
  • Issue and Outstanding: 14,225,900 - 03/07/2018

 


Recent Filings from (NASDAQ: GEMP)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 08 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 08 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 03 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: May, 03 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 17 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 12 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 20 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 15 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 13 2018

 

 


Daily Technical Chart for (NASDAQ: GEMP)

Daily Technical Chart for (NASDAQ: GEMP)


Stay tuned for daily updates and more on (NASDAQ: GEMP)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: GEMP)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

OTC Report
@OTCReporter

 

 


Disclaimer: OTC Report publishes reports providing information on selected companies. OTC Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. OTC Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in GEMP is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. OTC Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. OTC Report does not own any shares of GEMP and does not buy, sell, or trade any shares of GEMP. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by OTC Report. All rights reserved. Our Full Disclaimer: http://otc.report/disclaimer/